QT "derisking," mandated for all drugs, has become simpler and inexpensive to confidently achieve in early-phase clinical studies. Learn how to acquire continuous ECG data with small N and analyze by methods translated from preclinical to human.

Learning Objectives:
Discuss the safety and regulatory imperatives for cardiac safety studies
Identify the need for research/analytic methods that translate across preclinical and clinical development
Explain how to better choose the available options for when and how to "derisk" a drug in development.